Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v. - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - capecitabine teva is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes’ stage c) colon cancer.capecitabine teva is indicated for the treatment of metastatic colorectal cancer.capecitabine teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.capecitabine teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. capecitabine teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel (as hydrogen sulfate) - acute coronary syndrome; peripheral vascular diseases; myocardial infarction; stroke - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v.  - clopidogrel (as hydrochloride) - myocardial infarction; peripheral vascular diseases; stroke - antithrombotic agents - clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillation in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v. - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v. - irbesartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v.  - lamivudine - hiv infections - antivirals for systemic use - lamivudine teva pharma b.v. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv)-infected adults and children.

Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v. - raloxifene hydrochloride - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.when determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - fractures, bone; cancer - drugs for treatment of bone diseases - prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

teva b.v. - pregabalin - capsules hard - 225 milligram - antiepileptics - antiepileptics, other antiepileptics - it a is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of generalised anxiety disorder (gad) in adults